SYDNEY, March 31, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to Cantrixil for USD $1 million. Kazia to receive USD $1 million from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil In March 2021, Vivesto licensed the exclusive global development and commercialization rights for Cantr ...

SYDNEY, Feb. 20, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced a research grant awarded from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to fund research between The Hebrew University of Jerusalem (Hebrew University) and Kazia to explore the therapeutic potential of paxalisib as a treatment for Parkinson's disease (PD). The grant will fund collaborative preclinical studies at Professo ...

SYDNEY, Jan. 30, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer. This novel treatment combination offers what is believed to be a unique approach to targeting this highly aggressive and treatment-resistant type of breast cancer.The ABC-Pax (Advanced Breast Cancer – Paxalisi ...

SYDNEY, Jan. 14, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has closed its previously announced registered direct offering with existing fundamental healthcare investor, Alumni Capital LP, of 1,333,333 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing 100 ordinary shares of the Company, at a purchase price of $1.50 per ADS (or AD ...

Core Viewpoint - Kazia Therapeutics Limited has announced a definitive agreement for the purchase and sale of up to 1,333,333 American Depositary Shares (ADSs) at a price of $1.50 per ADS, aiming to raise approximately $2.0 million in gross proceeds for general corporate purposes [1][3]. Group 1: Offering Details - The offering includes a registered direct offering and a concurrent private placement of unregistered warrants to purchase an equal number of ADSs [1][2]. - The warrants will have an exercise price of $1.50 per ADS, will be immediately exercisable, and will expire five and a half years from issuance [1]. - The closing of the offering is expected around January 13, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for general corporate purposes, which may encompass working capital, research expenses, clinical development, and administrative costs [3]. Group 3: Company Overview - Kazia Therapeutics is an oncology-focused drug development company based in Sydney, Australia, with its lead program being paxalisib, aimed at treating various forms of brain cancer [7]. - Paxalisib has undergone ten clinical trials, with a pivotal study in glioblastoma expected to present data in late 2024 [7]. - The company is also developing EVT801, a small-molecule inhibitor of VEGFR3, which has shown promise in preclinical studies [8].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCH ...

Company and FDA to meet in December to discuss potential pathways to registration of paxalisib in glioblastoma multiforme (GBM)Company updates to corporate presentation and participation in upcoming medical meetings SYDNEY, Nov. 4, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced that the U.S. Food and Drug Administration (FDA) has granted a Type C meeting with the Company in December 2024 to discuss the potential pathways to registratio ...

SYDNEY, Sept. 12, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncologyfocused drug development company, is pleased to announce that an agreement has been executed with QIMR Berghofer Medical Research Institute, one of Australia's foremost cancer research centres, to obtain an exclusive license to certain intellectual property rights in relation to combination therapies consisting of PI3K inhibitor drugs, and one or more immunotherapy or PARP inhibitor drugs (PI3K combination). Under t ...

Core Viewpoint - Kazia Therapeutics is a biotechnology company focused on developing oncology drugs, particularly paxalisib for glioblastoma, which has shown promising clinical trial results [2][8]. Group 1: Company Overview - Kazia Therapeutics is an Australian biotechnology firm specializing in oncology drug development [2]. - The company's primary drug in development is paxalisib, which recently completed a phase II/III study for glioblastoma treatment [2]. Group 2: Clinical Trial Results - Paxalisib demonstrated a 3.8-month improvement in overall survival, representing an approximate 33% improvement for selected glioblastoma patients compared to the standard of care [8]. - The drug was well tolerated during the study, marking significant progress for Kazia Therapeutics [8]. Group 3: Stock Performance - Kazia Therapeutics' stock price surged from $0.20 to a 52-week high of $1.58 before dropping to $0.53 [3]. - The volatility in stock price reflects the unpredictable nature of biotech investments [5][7]. Group 4: Future Prospects - Kazia Therapeutics plans to release full data from the paxalisib study at a scientific meeting later this year, which could influence future stock performance [9]. - The company intends to meet with the U.S. FDA to discuss the results and explore a potential path to accelerated approval for paxalisib [10].

Core Viewpoint - Kazia Therapeutics has reported significant positive data from its phase II/III study of paxalisib for glioblastoma, leading to a substantial increase in its stock price and plans for potential FDA accelerated approval [4][3]. Company Overview - Kazia Therapeutics is an Australia-based clinical-stage company focused on developing drugs for oncology indications [1]. Study Results - The recent study showed that paxalisib-treated patients had a median overall survival (OS) of 15.7 months compared to 12.7 months for those receiving standard chemotherapy [2]. - In a secondary analysis, newly diagnosed unmethylated (NDU) patients treated with paxalisib achieved a median OS of 15.54 months, representing a 3.8-month improvement (nearly 33%) over the control group [5][10]. - The primary analysis indicated a median OS of 14.77 months for paxalisib in NDU patients, which was slightly better than the 13.84 months for the standard of care [15]. Stock Performance - Kazia's shares have surged 489.6% in the past week following the positive study results, and have increased 182.2% year to date, contrasting with a 5.1% decline in the industry [4][13]. Future Plans - The company plans to request a meeting with the FDA to explore a potential pathway for accelerated approval of paxalisib [3]. Study Context - The GBM AGILE study, which evaluates multiple therapies for glioblastoma, has completed enrollment for paxalisib, making it the third drug to do so [16].